Abstral REMS Sets Stage For Risk Reduction Plans For Similar Fentanyls

FDA's decision to create a class Risk Evaluation and Mitigation Strategy for all transmucosal fentanyl products indicates that the agency could take a similar strategy with the extended-release opioids.